Brief: Voyager Therapeutics Enters Capsid License Agreement And Strategic Collaboration With Novartis To Advance Novel Gene Therapies
02/01/2024 12:31
Jan 2 (Reuters) - Voyager Therapeutics Inc VYGR.O :
* VOYAGER THERAPEUTICS ENTERS CAPSID LICENSE AGREEMENT AND
STRATEGIC COLLABORATION WITH NOVARTIS TO ADVANCE NOVEL GENE
THERAPIES
Source text for Eikon: ID:nGNX9T8MXH
Further company coverage: VYGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview